In the case of Rani , where we are working to improve the lives of millions of people , I had to look at all of the ways that previous approaches have failed in order to come up with a radically different way to solve the problem . Rather than try to change the drug to make it viable orally , which had been tried many times before by other companies , I decided we needed to take a very different approach and instead change how the drug is delivered . Out of that concept , the RaniPill™ capsule was born .
What ’ s on the horizon for you , and for Rani Therapeutics ? Where do you see your roadmap taking you in 2020 and beyond ? It ’ s an exciting time for Rani Therapeutics . We ’ ve done hundreds of preclinical studies by delivering more than 1,000 capsules . We ’ ve tested nine drugs , including insulin , GLP-1 [ for diabetes ] and Humira [ for arthritis ] and we ’ ve demonstrated that the RaniPill™ capsule delivery is equivalent to subcutaneous injection . Later this year , we ’ ll be testing a drug called Octreotide which treats patients suffering from acromegaly , a condition resulting from the body ’ s pituitary gland producing an excessive amount of growth hormone . Next year , we ’ ll be testing several other drugs in Phase 1 studies . We are getting closer to bringing the RaniPill™ capsule to patients and improving the lives of millions . It ’ s an enormous challenge that keeps us focused and motivated every day .
53
europe . businesschief . com